Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free MPT Stock Alerts

Medical Properties Trust (MPT) Financials

Medical Properties Trust logo
$5.05 -0.13 (-2.51%)
As of 02:11 PM Eastern
Compare
Annual Income Statements for Medical Properties Trust

Annual Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 140 225 290 1,017 375 431 656 903 -556 -2,410 -277
Consolidated Net Income / (Loss)		 140 226 291 1,018 376 432 657 904 -556 -2,408 -276
Net Income / (Loss) Continuing Operations		 140 226 291 1,018 376 432 657 904 -556 -2,408 -276
Total Pre-Tax Income 		140 219 294 1,019 374 463 731 960 -687 -2,364 -237
Total Revenue		 442 541 705 785 616 921 1,177 1,543 461 578 462
Net Interest Income / (Expense)		 0.00 0.00 0.00 162 -238 -329 -367 0.00 -411 -418 -510
Total Interest Income		 0.00 0.00 0.00 162 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 0.00 0.00 238 329 367 0.00 411 418 510
Long-Term Debt Interest Expense		 - - - - 238 329 367 - 411 418 510
Total Non-Interest Income		 442 541 705 622 854 1,249 1,545 1,543 872 996 972
Other Service Charges		 112 108 129 - 150 142 169 166 69 49 44
Other Non-Interest Income		 330 433 576 622 704 1,107 1,376 1,377 803 947 928
Total Non-Interest Expense		 179 359 396 495 294 421 506 898 791 609 432
Other Operating Expenses		 44 211 241 314 120 157 185 520 187 161 167
Depreciation Expense		 70 94 125 133 152 264 321 333 603 448 265
Nonoperating Income / (Expense), net		 -123 37 -15 729 51 -36 60 315 -357 -2,333 -267
Income Tax Expense		 - -6.83 2.68 0.93 -2.62 31 74 56 -131 44 39
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.33 0.89 1.45 1.79 1.72 0.82 0.92 1.22 0.38 1.98 1.11
Basic Earnings per Share		 $0.64 $0.86 $0.82 $2.77 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02) ($0.46)
Weighted Average Basic Shares Outstanding		 218.00M 260.41M 349.90M 365.36M 427.08M 529.24M 588.82M 598.63M 598.52M 600.25M 600.89M
Diluted Earnings per Share		 $0.63 $0.86 $0.82 $2.76 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02) ($0.46)
Weighted Average Diluted Shares Outstanding		 218.30M 261.07M 350.44M 366.27M 428.30M 530.46M 590.14M 598.84M 598.52M 600.25M 600.89M
Weighted Average Basic & Diluted Shares Outstanding		 218.10M 261.70M 353.40M 367M 520.93M 580M 599.90M 598.30M 599.10M 600.60M 597.70M
Cash Dividends to Common per Share		 $0.87 $0.90 $0.95 $0.99 $1.01 $1.07 $1.11 $1.15 $1.17 $0.38 $0.32

Quarterly Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 117 -664 -876 -321 -801 -413 -118 -98 -78 17 33
Consolidated Net Income / (Loss)		 117 -664 -875 -320 -801 -412 -118 -98 -77 18 33
Net Income / (Loss) Continuing Operations		 117 -664 -875 -320 -801 -412 -118 -98 -77 18 33
Total Pre-Tax Income 		127 -660 -864 -305 -792 -403 -109 -88 -67 26 0.29
Total Revenue		 200 -427 163 165 120 130 108 111 105 138 119
Net Interest Income / (Expense)		 -107 -337 -109 -101 -106 -101 -116 -130 -132 -132 -133
Total Interest Income		 0.00 -32 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Interest Expense		 107 304 109 101 106 101 116 130 132 132 133
Long-Term Debt Interest Expense		 107 - 109 101 106 101 116 130 132 132 133
Total Non-Interest Income		 307 -90 271 267 226 232 224 240 238 270 252
Other Service Charges		 30 - 11 17 9.71 11 8.58 13 10 12 10
Other Non-Interest Income		 277 -69 260 250 216 220 215 227 227 258 242
Total Non-Interest Expense		 122 -91 114 145 246 103 114 104 114 101 112
Other Operating Expenses		 45 -169 38 43 42 38 49 37 47 34 42
Depreciation Expense		 78 77 76 102 205 65 65 67 67 67 70
Nonoperating Income / (Expense), net		 49 -324 -913 -325 -665 -430 -103 -95 -58 -11 -6.59
Income Tax Expense		 10 3.98 11 15 9.03 9.56 9.44 9.80 11 8.51 -33
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.19 0.36 0.25 0.98 0.23 0.53 0.26 0.29 0.28 0.28 0.28
Basic Earnings per Share		 $0.19 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68) ($0.20) ($0.16) ($0.13) $0.03 $0.05
Weighted Average Basic Shares Outstanding		 598.44M 598.52M 600.30M 600.06M 600.23M 600.25M 600.59M 600.81M 601.14M 600.89M 597.72M
Diluted Earnings per Share		 $0.19 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68) ($0.20) ($0.16) ($0.13) $0.03 $0.05
Weighted Average Diluted Shares Outstanding		 598.55M 598.52M 600.30M 600.06M 600.23M 600.25M 600.59M 600.81M 601.14M 600.89M 597.72M
Weighted Average Basic & Diluted Shares Outstanding		 599M 599.10M 600.10M 600.20M 600.40M 600.60M 600.80M 601.10M 601.50M 597.70M 598.10M
Cash Dividends to Common per Share		 $0.15 - $0.00 $0.30 $0.08 - $0.08 $0.08 $0.08 - $0.09

Annual Cash Flow Statements for Medical Properties Trust

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 62 -110 70 667 652 -928 -99 -207 3.02 84 194
Net Cash From Operating Activities		 207 264 362 449 494 618 812 739 506 245 231
Net Cash From Continuing Operating Activities		 207 264 362 449 499 618 812 739 506 245 231
Net Income / (Loss) Continuing Operations		 140 226 291 1,018 376 432 657 904 -556 -2,408 -276
Consolidated Net Income / (Loss)		 140 226 291 1,018 376 432 657 904 -556 -2,408 -276
Depreciation Expense		 72 98 132 141 157 276 334 346 616 454 273
Amortization Expense		 6.09 7.61 6.52 7.36 8.88 13 17 17 16 17 26
Non-Cash Adjustments to Reconcile Net Income		 -26 -76 -44 906 -95 -101 -209 -441 555 2,193 173
Changes in Operating Assets and Liabilities, net		 15 9.13 -24 -34 53 -2.60 13 -87 -125 -9.85 34
Net Cash From Investing Activities		 -1,946 -927 -2,362 564 -4,884 -2,947 -3,858 396 518 1,318 -265
Net Cash From Continuing Investing Activities		 -1,946 -927 -2,362 564 -4,884 -2,947 -3,858 396 518 1,318 -265
Purchase of Property, Leasehold Improvements and Equipment		 -146 -171 -74 - -84 -68 -68 -109 -114 -80 -80
Purchase of Investment Securities		 -2,590 -1,911 -2,361 - -4,913 -4,348 -5,698 -1,748 -780 -682 -422
Sale and/or Maturity of Investments		 791 1,156 73 4,181 113 1,470 1,908 2,253 1,412 2,080 237
Net Cash From Financing Activities		 1,801 553 2,070 -346 5,042 1,401 2,948 -1,343 -1,020 -1,479 228
Net Cash From Continuing Financing Activities		 1,801 553 2,070 -252 5,042 1,812 2,948 -1,343 -1,020 -1,479 228
Net Change in Deposits		 -11 15 28 21 -12 22 18 -5.02 10 2.24 -3.20
Issuance of Debt		 1,190 1,000 2,906 760 2,983 2,379 3,968 129 568 -327 2,513
Issuance of Common Equity		 817 1,174 548 188 2,533 411 1,051 0.00 0.00 0.00 0.00
Repayment of Debt		 -0.28 -1,385 -1,038 -812 0.00 -800 -1,391 -666 -988 -702 -2,011
Repurchase of Common Equity		 - - - - - 0.00 0.00 -18 0.00 0.00 -23
Payment of Dividends		 -183 -218 -327 364 -412 -568 -643 -699 -615 -321 -193
Other Financing Activities, Net		 -13 -32 -46 -3.61 -50 369 -54 -84 5.18 -132 -54
Cash Interest Paid		 214 278 150 222 211 310 326 354 406 420 458

Quarterly Cash Flow Statements for Medical Properties Trust

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 30 -97 -23 384 - 69 675 -351 -222 92 -114
Net Cash From Operating Activities		 158 135 74 35 - 77 0.77 103 37 89 -14
Net Cash From Continuing Operating Activities		 158 135 28 35 - 204 50 149 77 -45 21
Net Income / (Loss) Continuing Operations		 117 -664 -875 -320 - -412 -236 -196 -155 311 33
Consolidated Net Income / (Loss)		 117 -664 -875 -320 - -412 -236 -196 -155 311 33
Depreciation Expense		 81 80 77 104 - 66 131 136 139 -133 73
Amortization Expense		 3.88 3.80 3.70 3.79 - 5.08 12 13 14 -12 6.98
Non-Cash Adjustments to Reconcile Net Income		 -20 727 834 308 - 519 205 156 119 -306 -31
Changes in Operating Assets and Liabilities, net		 -23 -12 -12 -61 - 26 -61 40 -40 95 -61
Net Cash From Investing Activities		 -62 170 -119 1,202 - 92 -179 -145 -190 249 -77
Net Cash From Continuing Investing Activities		 -62 170 -119 1,202 - 92 -83 -125 -116 59 -77
Purchase of Property, Leasehold Improvements and Equipment		 -52 -34 -30 -15 - -16 - - - - -13
Purchase of Investment Securities		 -232 -106 -222 -289 - 16 -122 -187 -229 117 -131
Sale and/or Maturity of Investments		 223 310 133 1,507 - 92 40 62 112 23 67
Net Cash From Financing Activities		 -67 -403 22 -854 - -100 853 -310 -69 -246 -23
Net Cash From Continuing Financing Activities		 -67 -403 22 -854 - -100 336 -100 -97 -4.71 -23
Net Change in Deposits		 0.60 2.39 6.23 2.28 - 2.96 6.49 -2.55 1.01 -8.15 4.41
Issuance of Debt		 427 141 0.00 693 - -12 5,026 - - -2,513 30
Repayment of Debt		 -319 -454 109 -1,381 - -39 -4,505 - - 2,494 0.00
Payment of Dividends		 -174 -91 -93 -90 - -48 -96 -97 -97 96 -55
Other Financing Activities, Net		 -0.72 -0.98 -0.28 -78 - -3.76 -95 -0.91 -1.47 -51 -2.29
Effect of Exchange Rate Changes		 - - - - - - - - - - -1.79
Cash Interest Paid		 95 84 132 123 - 71 236 205 346 -328 174

Annual Balance Sheets for Medical Properties Trust

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 5,609 6,419 9,020 8,844 14,467 16,829 20,520 19,658 18,305 14,295 15,002
Cash and Due from Banks		 196 83 171 821 1,462 550 459 236 250 332 541
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 2,992 3,968 5,307 4,781 7,312 10,750 - 12,468 - 10,456 10,543
Mortgage Servicing Rights		 758 1,060 1,778 1,213 1,275 248 213 364 309 120 124
Other Assets		 1,433 1,043 1,369 1,156 2,934 2,964 3,239 5,381 2,663 4,005 3,795
Total Liabilities & Shareholders' Equity		 5,609 6,419 9,020 8,844 14,467 16,829 20,520 19,658 18,305 14,295 15,002
Total Liabilities		 3,502 3,165 5,185 4,283 7,439 9,485 12,074 11,064 10,671 9,461 10,395
Long-Term Debt		 3,323 2,909 4,899 4,037 7,024 8,865 11,283 10,268 10,064 8,848 9,698
Other Long-Term Liabilities		 29 20 229 41 554 181 791 174 607 613 697
Total Equity & Noncontrolling Interests		 2,107 3,253 3,835 4,561 7,028 7,344 8,446 8,594 7,634 4,834 4,607
Total Preferred & Common Equity		 2,102 3,248 3,821 4,547 7,028 7,339 8,440 8,593 7,632 4,833 4,606
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,102 3,248 3,821 4,547 14,119 7,339 8,440 8,593 7,632 4,833 4,606
Common Stock		 2,594 3,776 4,333 4,443 14,029 7,462 8,565 8,536 8,561 8,586 8,574
Retained Earnings		 -419 -434 -486 163 83 -71 -88 116 -972 -3,659 -4,136
Accumulated Other Comprehensive Income / (Loss)		 -73 -93 -26 -58 -63 -51 -37 -59 43 -94 168
Noncontrolling Interest		 5.00 4.85 15 14 0.11 5.33 5.48 1.57 2.27 1.05 1.05

Quarterly Balance Sheets for Medical Properties Trust

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 19,043 8,890 19,204 19,005 17,301 16,195 15,236 14,854 15,150 14,924 14,763
Cash and Due from Banks		 299 707 324 340 224 607 276 673 510 397 425
Loans and Leases, Net of Allowance		 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 - - - - - 11,949 11,654 - - - 10,396
Mortgage Servicing Rights		 306 - 299 302 310 399 298 121 124 128 124
Other Assets		 6,444 - 6,699 6,635 5,366 4,658 4,432 4,050 4,224 4,284 3,817
Total Liabilities & Shareholders' Equity		 19,043 8,890 19,204 19,005 17,301 16,195 15,236 14,854 15,150 14,924 14,763
Total Liabilities		 10,210 6,380 10,890 10,719 10,597 10,002 9,795 10,092 10,317 10,263 10,217
Long-Term Debt		 9,476 972 10,238 10,157 10,099 9,369 9,216 9,465 9,649 9,616 9,663
Other Long-Term Liabilities		 165 - 207 186 195 186 161 175 173 171 554
Total Equity & Noncontrolling Interests		 8,833 2,509 8,315 8,285 6,704 6,193 5,441 4,762 4,834 4,661 4,546
Total Preferred & Common Equity		 8,832 2,498 8,314 8,285 6,702 6,190 5,439 4,761 4,833 4,660 4,545
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 8,832 2,498 8,314 8,285 6,702 6,190 5,439 4,761 4,833 4,660 4,545
Common Stock		 8,538 3,492 8,548 8,559 8,568 8,572 8,579 8,591 8,599 8,604 8,578
Retained Earnings		 433 3,946 -241 -215 -1,847 -2,348 -3,198 -3,825 -3,972 -4,098 -4,157
Accumulated Other Comprehensive Income / (Loss)		 -139 -452 6.68 -60 -19 -34 57 -4.82 206 155 124
Noncontrolling Interest		 1.47 11 0.90 0.89 2.27 2.90 2.54 1.05 1.05 1.05 1.05

Annual Metrics And Ratios for Medical Properties Trust

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 237,837,152.00 320,247,632.00 364,156,080.00 364,941,199.00 517,440,399.00 535,996,738.00 596,300,000.00 598,000,000.00 599,000,000.00 600,400,000.00 601,500,000.00
DEI Adjusted Shares Outstanding		 237,837,152.00 320,247,632.00 364,156,080.00 364,941,199.00 517,440,399.00 535,996,738.00 596,300,000.00 598,000,000.00 599,000,000.00 600,400,000.00 601,500,000.00
DEI Earnings Per Adjusted Shares Outstanding		 0.59 0.71 0.80 2.79 0.73 0.81 1.10 1.51 -0.93 -4.01 -0.46
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.64 $0.86 $0.82 $2.77 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 218.00M 260.41M 349.90M 365.36M 427.08M 529.24M 588.82M 598.63M 598.52M 600.25M 600.89M
Adjusted Diluted Earnings per Share		 $0.63 $0.86 $0.82 $2.76 $0.87 $0.81 $1.11 $1.50 ($0.93) ($4.02) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 218.30M 261.07M 350.44M 366.27M 428.30M 530.46M 590.14M 598.84M 598.52M 600.25M 600.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.87 $0.00 $1.11 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 237.85M 320.93M 364.69M 381.08M 520.93M 580M 599.90M 598.30M 599.10M 600.60M 597.70M
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Medical Properties Trust

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 598,400,000.00 599,000,000.00 599,100,000.00 600,100,000.00 600,200,000.00 600,400,000.00 600,600,000.00 600,800,000.00 600,800,000.00 601,500,000.00 597,700,000.00
DEI Adjusted Shares Outstanding		 598,400,000.00 599,000,000.00 599,100,000.00 600,100,000.00 600,200,000.00 600,400,000.00 600,600,000.00 600,800,000.00 600,800,000.00 601,500,000.00 597,700,000.00
DEI Earnings Per Adjusted Shares Outstanding		 0.20 -1.11 -1.46 -0.53 -1.33 -0.69 -0.20 -0.16 -0.13 0.03 0.06
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -24.37% -103.35% -53.56% -51.06% -40.17% 2,904.12% -33.59% -32.99% -12.09% - 9.94%
EBITDA Growth		 -28.11% -202.68% -38.62% -29.25% -51.87% 139.10% 5.50% 22.90% 84.80% - -36.32%
EBIT Growth		 -43.37% -314.50% -59.22% 110.38% -263.81% 108.09% -111.29% -65.46% 93.23% - 224.51%
NOPAT Growth		 -43.49% -308.02% -68.39% 110.38% -224.54% 108.09% -111.29% -65.46% 93.23% - 20,762.56%
Net Income Growth		 -47.35% -373.27% -2,750.25% -653.33% -785.17% 37.86% 86.52% 69.32% 90.33% - 128.05%
EPS Growth		 -48.65% -358.33% -3,020.00% -671.43% -805.26% 38.18% 86.30% 70.37% 90.30% - 125.00%
Operating Cash Flow Growth		 -26.04% -25.22% -45.19% -53.93% 0.00% -43.37% -98.97% 193.53% 0.00% - -1,956.64%
Free Cash Flow Firm Growth		 -108.16% -4.97% 699.61% 844.25% 6,084.82% 333.94% 21.74% -63.91% -89.90% - -68.21%
Invested Capital Growth		 0.73% -6.17% -11.01% -16.12% -20.53% -22.69% -15.33% -6.94% -2.59% - -0.13%
Revenue Q/Q Growth		 -40.76% -107.84% 1,137.58% 1.54% -27.58% 267.54% -75.43% 2.46% -4.99% - -13.89%
EBITDA Q/Q Growth		 -10.15% -255.40% 151.56% -1.73% -38.87% 16.72% 39.11% 14.48% -8.09% - 179.81%
EBIT Q/Q Growth		 140.40% -533.01% 114.57% -59.29% -737.74% 121.40% -120.33% 224.51% -225.03% - -81.25%
NOPAT Q/Q Growth		 153.14% -429.19% 114.57% -59.29% -737.74% 121.40% -120.33% 224.51% -225.03% - 3,131.20%
Net Income Q/Q Growth		 375.48% -667.68% -31.92% 63.48% -150.56% 48.52% 71.38% 16.90% 21.02% - 88.14%
EPS Q/Q Growth		 371.43% -678.95% -32.73% 63.01% -148.15% 49.25% 70.59% 20.00% 18.75% - 66.67%
Operating Cash Flow Q/Q Growth		 106.71% -14.40% -45.10% -52.57% 0.00% 29.55% -99.00% 13,375.78% -64.11% - -115.96%
Free Cash Flow Firm Q/Q Growth		 -119.42% 1,605.42% 127.18% 42.20% 23.06% 9.15% -36.27% -57.85% -65.57% - 236.59%
Invested Capital Q/Q Growth		 -0.59% -4.04% -5.06% -7.39% -5.82% -6.65% 3.99% 1.79% -1.42% - -0.68%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 81.05% 0.00% 79.81% 77.24% 65.20% 22.40% 126.79% 141.67% 137.06% - 73.44%
EBIT Margin		 38.76% 0.00% 30.06% 12.05% -106.13% 6.18% -5.11% 6.21% -8.17% - 5.79%
Profit (Net Income) Margin		 58.49% 0.00% -538.26% -193.58% -669.76% -93.81% -109.28% -88.63% -73.67% - 27.88%
Tax Burden Percent		 92.08% 100.60% 101.27% 104.77% 101.14% 102.37% 108.69% 111.11% 116.33% - 11,616.49%
Interest Burden Percent		 163.87% 196.62% -1,768.51% -1,533.18% 623.98% -1,483.29% 1,967.01% -1,284.23% 774.79% - 4.15%
Effective Tax Rate		 7.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -11,516.49%
Return on Invested Capital (ROIC)		 2.63% 0.00% 0.81% 0.25% -1.94% 0.27% -0.22% 0.26% -0.34% - 22.34%
ROIC Less NNEP Spread (ROIC-NNEP)		 3.10% 0.00% -8.05% -3.15% -9.29% -4.29% -1.38% -0.83% -1.10% - 14.34%
Return on Net Nonoperating Assets (RNNOA)		 3.55% 0.00% -10.92% -4.26% -13.11% -6.50% -2.36% -1.42% -2.06% - 29.47%
Return on Equity (ROE)		 6.19% 0.00% -10.11% -4.00% -15.05% -6.23% -2.58% -1.17% -2.40% - 51.81%
Cash Return on Invested Capital (CROIC)		 -0.12% 5.11% 10.08% 16.75% 21.21% 25.46% 16.22% 6.73% 2.72% - 0.34%
Operating Return on Assets (OROA)		 2.76% 0.00% 1.11% 0.35% -2.68% 0.38% -0.30% 0.35% -0.47% - 0.18%
Return on Assets (ROA)		 4.17% 0.00% -19.93% -5.60% -16.89% -5.73% -6.40% -5.01% -4.26% - 0.89%
Return on Common Equity (ROCE)		 6.19% 0.00% -10.11% -4.00% -15.04% -6.23% -2.58% -1.17% -2.40% - 51.80%
Return on Equity Simple (ROE_SIMPLE)		 -0.40% 0.00% -21.85% -28.14% -48.90% 0.00% -34.68% -29.58% -15.15% - -2.75%
Net Operating Profit after Tax (NOPAT)		 71 -235 34 14 -89 19 -3.86 4.81 -6.02 - 798
NOPAT Margin		 35.69% 0.00% 21.04% 8.44% -74.29% 4.32% -3.58% 4.35% -5.72% - 672.42%
Net Nonoperating Expense Percent (NNEP)		 -0.46% 4.22% 8.86% 3.40% 7.35% 4.56% 1.17% 1.08% 0.76% - 8.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 61.24% 0.00% 69.94% 87.95% 206.13% 93.82% 105.11% 93.79% 108.17% - 94.21%
Earnings before Interest and Taxes (EBIT)		 77 -335 49 20 -127 27 -5.52 6.87 -8.59 - 6.87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 162 -252 130 128 78 98 137 157 144 - 87
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.35 0.35 0.38 0.38 0.60 0.49 0.76 0.53 0.65 - 0.61
Price to Tangible Book Value (P/TBV)		 0.00 0.35 0.00 0.31 0.48 0.49 0.00 0.00 0.00 - 0.61
Price to Revenue (P/Rev)		 2.17 3.07 3.69 4.64 7.59 2.38 3.85 2.87 3.49 - 5.86
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 20.79% 19.71% 20.86% 15.16% 9.70% 11.65% 8.96% 7.56% 6.31% - 7.34%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.69 0.71 0.74 0.72 0.83 0.80 0.87 0.81 0.86 - 0.85
Enterprise Value to Revenue (EV/Rev)		 9.41 14.33 18.13 21.76 28.31 10.94 13.19 13.18 14.07 - 25.42
Enterprise Value to EBITDA (EV/EBITDA)		 15.96 41.36 56.29 66.47 135.88 24.74 27.76 38.60 22.88 - 43.07
Enterprise Value to EBIT (EV/EBIT)		 78.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 616.02 - 287.19
Enterprise Value to NOPAT (EV/NOPAT)		 115.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 880.02 - 410.26
Enterprise Value to Operating Cash Flow (EV/OCF)		 23.13 24.70 27.91 27.63 40.17 44.36 72.22 0.00 56.25 - 55.65
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 13.38 6.90 3.90 3.48 2.73 4.93 11.56 31.19 - 248.45
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.23 1.32 1.51 1.51 1.69 1.83 1.99 2.00 2.06 - 2.13
Long-Term Debt to Equity		 1.23 1.32 1.51 1.51 1.69 1.83 1.99 2.00 2.06 - 2.13
Financial Leverage		 1.15 1.25 1.36 1.35 1.41 1.52 1.71 1.72 1.86 - 2.06
Leverage Ratio		 2.22 2.34 2.44 2.44 2.49 2.61 2.80 2.84 2.99 - 3.18
Compound Leverage Factor		 3.64 4.60 -43.14 -37.41 15.57 -38.78 55.16 -36.51 23.13 - 0.13
Debt to Total Capital		 55.07% 56.87% 60.10% 60.20% 62.88% 64.67% 66.53% 66.62% 67.35% - 68.01%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 55.07% 56.87% 60.10% 60.20% 62.88% 64.67% 66.53% 66.62% 67.35% - 68.01%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.01% 0.01% 0.02% 0.02% 0.01% 0.01% 0.01% 0.01% - 0.01%
Common Equity to Total Capital		 44.92% 43.12% 39.89% 39.78% 37.11% 35.32% 33.46% 33.37% 32.64% - 31.99%
Debt to EBITDA		 12.71 33.32 45.83 55.90 102.47 20.10 21.16 31.87 17.93 - 34.66
Net Debt to EBITDA		 12.29 32.50 44.81 52.28 99.40 19.35 19.66 30.19 17.19 - 33.14
Long-Term Debt to EBITDA		 12.71 33.32 45.83 55.90 102.47 20.10 21.16 31.87 17.93 - 34.66
Debt to NOPAT		 92.19 -43.58 -35.99 -70.74 -33.45 -408.04 -158.38 -140.08 689.87 - 330.19
Net Debt to NOPAT		 89.10 -42.50 -35.19 -66.16 -32.45 -392.71 -147.11 -132.68 661.42 - 315.66
Long-Term Debt to NOPAT		 92.19 -43.58 -35.99 -70.74 -33.45 -408.04 -158.38 -140.08 689.87 - 330.19
Noncontrolling Interest Sharing Ratio		 0.01% 0.00% 0.03% 0.03% 0.02% 0.03% 0.03% 0.04% 0.04% - 0.02%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -62 930 2,113 3,004 3,697 4,035 2,572 1,084 373 - 817
Operating Cash Flow to CapEx		 303.81% 401.63% 248.76% 232.03% 0.00% 471.83% 0.00% 0.00% 0.00% - -112.13%
Free Cash Flow to Firm to Interest Expense		 -0.58 0.00 19.44 29.62 34.80 0.00 22.21 8.36 2.82 - 6.13
Operating Cash Flow to Interest Expense		 1.48 0.00 0.68 0.35 0.00 0.00 0.01 0.80 0.28 - -0.11
Operating Cash Flow Less CapEx to Interest Expense		 0.99 0.00 0.41 0.20 0.00 0.00 0.01 0.80 0.28 - -0.20
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.05 0.04 0.03 0.03 0.06 0.06 0.06 0.06 - 0.03
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 18,442 17,698 16,803 15,562 14,657 13,682 14,227 14,483 14,278 - 14,208
Invested Capital Turnover		 0.07 0.05 0.04 0.03 0.03 0.06 0.06 0.06 0.06 - 0.03
Increase / (Decrease) in Invested Capital		 133 -1,165 -2,078 -2,990 -3,786 -4,016 -2,576 -1,079 -379 - -19
Enterprise Value (EV)		 12,754 12,491 12,404 11,141 12,221 10,888 12,415 11,685 12,267 - 12,006
Market Capitalization		 2,936 2,675 2,527 2,375 3,278 2,372 3,622 2,545 3,046 - 2,767
Book Value per Share		 $13.84 $12.74 $11.19 $10.32 $9.06 $8.05 $7.93 $8.04 $7.75 - $7.60
Tangible Book Value per Share		 ($5.75) $12.74 ($7.84) $12.68 $11.43 $8.05 ($8.74) ($9.09) ($9.07) - $7.60
Total Capital		 18,442 17,698 16,803 15,562 14,657 13,682 14,227 14,483 14,278 - 14,208
Total Debt		 10,157 10,064 10,099 9,369 9,216 8,848 9,465 9,649 9,616 - 9,663
Total Long-Term Debt		 10,157 10,064 10,099 9,369 9,216 8,848 9,465 9,649 9,616 - 9,663
Net Debt		 9,817 9,814 9,874 8,763 8,940 8,516 8,792 9,139 9,220 - 9,238
Capital Expenditures (CapEx)		 52 34 30 15 0.00 16 0.00 0.00 0.00 - 13
Net Nonoperating Expense (NNE)		 -46 429 910 334 712 431 114 103 71 - 765
Net Nonoperating Obligations (NNO)		 10,157 10,064 10,099 9,369 9,216 8,848 9,465 9,649 9,616 - 9,663
Total Depreciation and Amortization (D&A)		 85 84 81 108 205 71 142 150 153 - 80
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.19 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68) ($0.20) ($0.16) ($0.13) $0.03 $0.05
Adjusted Weighted Average Basic Shares Outstanding		 598.44M 598.52M 600.30M 600.06M 600.23M 600.25M 600.59M 600.81M 601.14M 600.89M 597.72M
Adjusted Diluted Earnings per Share		 $0.19 ($1.10) ($1.46) ($0.54) ($1.34) ($0.68) ($0.20) ($0.16) ($0.13) $0.03 $0.05
Adjusted Weighted Average Diluted Shares Outstanding		 598.55M 598.52M 600.30M 600.06M 600.23M 600.25M 600.59M 600.81M 601.14M 600.89M 597.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 599M 599.10M 600.10M 600.20M 600.40M 600.60M 600.80M 601.10M 601.50M 597.70M 598.10M
Normalized Net Operating Profit after Tax (NOPAT)		 71 -235 34 14 -89 19 -3.86 4.81 -6.02 - 4.81
Normalized NOPAT Margin		 35.69% 0.00% 21.04% 8.44% -74.29% 4.32% -3.58% 4.35% -5.72% - 4.05%
Pre Tax Income Margin		 63.52% 0.00% -531.53% -184.76% -662.21% -91.64% -100.54% -79.77% -63.33% - 0.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.73 0.00 0.45 0.20 -1.19 0.00 -0.05 0.05 -0.06 - 0.05
NOPAT to Interest Expense		 0.67 0.00 0.31 0.14 -0.84 0.00 -0.03 0.04 -0.05 - 5.99
EBIT Less CapEx to Interest Expense		 0.24 0.00 0.17 0.05 -1.19 0.00 -0.05 0.05 -0.06 - -0.04
NOPAT Less CapEx to Interest Expense		 0.18 0.00 0.04 -0.01 -0.84 0.00 -0.03 0.04 -0.05 - 5.89
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -2,133.72% -110.66% -36.30% -25.70% -13.69% -13.33% -19.66% 0.00% -47.86% - -122.01%
Augmented Payout Ratio		 -2,133.72% -110.66% -36.30% -25.70% -13.69% -13.33% -19.66% 0.00% -47.86% - -122.01%

Financials Breakdown Chart

Key Financial Trends

Here are the key trends for Medical Properties Trust (MPW), based on quarterly filings from 2022 through 2025. The bullets focus on revenue, earnings, cash flow, and balance-sheet dynamics relevant to retail investors.

  • Q4 2025 Operating Revenue rose to 4,713,100,000 from 4,399,700,000 in Q4 2024 (roughly +7%), signaling stronger topline performance.
  • Q4 2025 net income attributable to common shareholders was 30,200,000, turning positive after mid-2025 weakness (Q2 2025 net income was -67,100,000).
  • Q4 2025 diluted earnings per share (EPS) reached 0.65, up from 0.49 in Q4 2024, indicating improved profitability per share.
  • Q4 2025 operating cash flow was solid, with net cash from continuing operating activities of 178,900,000 (up from 59,800,000 in Q3 2025), showing improved cash generation in the quarter.
  • Net Change in Cash & Equivalents in Q4 2025 was 596,400,000, a sizable quarterly increase largely aided by financing activity.
  • Net cash from financing activities in Q4 2025 was 426,000,000, reflecting active financing activity (debt issuance of 586,600,000) that supported liquidity.
  • Balance-sheet size remains steady, with total assets around 8.447B and total liabilities about 6.435B in the latest quarter, leaving roughly 2.01B in equity.
  • Cash balances fluctuated across 2025, with cash and equivalents ranging roughly from 275M (Q3 2025) to 396M (Q1 2025) over the year.
  • Quarterly operating cash flow has been volatile, including negative OCF in Q1 2025 (-153.2M) and Q2 2025 (-189.6M).
  • Net income shows quarterly swings, with a negative print in Q2 2025 (-67.1M) followed by positives in later quarters.
05/15/26 12:39 PM ETAI Generated. May Contain Errors.

Medical Properties Trust Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Medical Properties Trust's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Medical Properties Trust's net income appears to be on a downward trend, with a most recent value of -$275.94 million in 2025, falling from $139.93 million in 2015. The previous period was -$2.41 billion in 2024. See Medical Properties Trust's forecast for analyst expectations on what's next for the company.

Over the last 10 years, Medical Properties Trust's total revenue changed from $441.88 million in 2015 to $461.66 million in 2025, a change of 4.5%.

Medical Properties Trust's total liabilities were at $10.39 billion at the end of 2025, a 9.9% increase from 2024, and a 196.8% increase since 2015.

In the past 10 years, Medical Properties Trust's cash and equivalents has ranged from $83.24 million in 2016 to $1.46 billion in 2019, and is currently $540.86 million as of their latest financial filing in 2025.


Related Companies

Financial statements for NYSE:MPT last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel